A 68-year-old man with severe PAH and multiple coexisting conditions experienced marked improvement after receiving combination therapy.| Pulmonary Hypertension News
Three months of CS1 therapy boosted quality of life, while symptoms tied to heart failure and clinical worsening and mortality risk declined.| Pulmonary Hypertension News
Cereno's expanded access program for investigational therapy CS1 covers 10 PAH patients, following a Phase 2a clinical trial.| Pulmonary Hypertension News
The investigational therapy CS1 led to beneficial changes in for people with pulmonary arterial hypertension in a Phase 2a clinical trial.| Pulmonary Hypertension News
The FDA has approved the use of Cereno Scientific’s CS1 in an extension of the ongoing Phase 2 trial testing the therapy in people with PAH.| Pulmonary Hypertension News
A 5-year-old boy with a neuroblastoma developed PAH after receiving a high dose of chemotherapy to prepare for a stem cell transplant.| Pulmonary Hypertension News
Researchers developed a tool for predicting the prognosis of people with chronic lung disease-related pulmonary hypertension.| Pulmonary Hypertension News
A larger diameter of the main pulmonary artery predicts poorer outcomes in pulmonary arterial hypertension (PAH) patients, a study found.| Pulmonary Hypertension News
The FDA has approved Yutrepia, an inhaled treprostinil formulation, for the treatment of PAH and PH-ILD, two forms of pulmonary hypertension.| Pulmonary Hypertension News
Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).| Pulmonary Hypertension News
Looking for information about pulmonary venous hypertension? PVH's causes, symptoms, diagnosis, and treatments are highlighted here.| Pulmonary Hypertension News
Mutations in certain genes can cause or increase the likelihood of someone developing PAH. This is known as familial or heritable PAH.| Pulmonary Hypertension News
No description.| Pulmonary Hypertension News
Increasing irisin, found at lower levels in people with PAH, may help slow disease progression by stopping vascular remodeling, per a study.| Pulmonary Hypertension News
A protein called BMPER found at low levels in models has emerged as a PAH treatment target as it may ease disease progression, per a study.| Pulmonary Hypertension News
A trial of Insmed’s TPIP suggests daily doses of the inhaled dry powder are well tolerated and may improve blood flow in adults with PAH.| Pulmonary Hypertension News
Platelets tend to cluster in lung blood vessels in people with decompensated pulmonary hypertension, increasing their risk of bleeding, a study says.| Pulmonary Hypertension News
Adding more lines of treatment may reduce the risk of rehospitalization among adults with PAH who are taking only one medication, per a study.| Pulmonary Hypertension News
Low-dose metformin delivered to the pulmonary arteries using lipid-based nanocapsules, safely eased signs of PAH in rats.| Pulmonary Hypertension News
Using a machine-learned algorithm, Corvista's system can accurately diagnose pulmonary hypertension in a noninvasive way, a study shows.| Pulmonary Hypertension News
Cereno Scientific reported a successful meeting with the FDA on the design of a future clinical trial for its PAH therapy candidate CS1.| Pulmonary Hypertension News
Heart failure related to PAH is becoming more common, with patients living fewer years in full health, a trend that’s predicted to continue.| Pulmonary Hypertension News
Pulmonary hypertension (PH) is a chronic and progressive disease associated with high blood pressure in the blood vessels that supply the lungs, known as the pulmonary arteries. Read more about PH here.| Pulmonary Hypertension News